Cargando…
Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes
Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets. iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide (Lixi), has been shown to provide robust HbA(1c) reductions allowing more...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004501/ https://www.ncbi.nlm.nih.gov/pubmed/33620694 http://dx.doi.org/10.1007/s12325-020-01614-5 |
_version_ | 1783671922423234560 |
---|---|
author | Skolnik, Neil Del Prato, Stefano Blonde, Lawrence Galstyan, Gagik Rosenstock, Julio |
author_facet | Skolnik, Neil Del Prato, Stefano Blonde, Lawrence Galstyan, Gagik Rosenstock, Julio |
author_sort | Skolnik, Neil |
collection | PubMed |
description | Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets. iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide (Lixi), has been shown to provide robust HbA(1c) reductions allowing more people to reach HbA(1c) targets compared with separate administration of iGlar or Lixi. The purpose of this review is to help clinicians understand treatment intensification using iGlarLixi by presenting typical clinical scenarios supported by research evidence. These cases will focus on individuals with T2D inadequately controlled by oral antihyperglycemic drugs, basal insulin, or glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and take into consideration T2D duration, body mass index, incidence of adverse events, and regimen simplicity. Clinical evidence on the efficacy, effectiveness, and safety of iGlarLixi from randomized controlled trials and real-world studies will be discussed in the context of these cases. |
format | Online Article Text |
id | pubmed-8004501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-80045012021-04-16 Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes Skolnik, Neil Del Prato, Stefano Blonde, Lawrence Galstyan, Gagik Rosenstock, Julio Adv Ther Review Treatment of type 2 diabetes (T2D) requires progressive therapy intensification to reach and maintain individualized glycemic targets. iGlarLixi, a fixed-ratio combination of insulin glargine 100 U/mL (iGlar) and lixisenatide (Lixi), has been shown to provide robust HbA(1c) reductions allowing more people to reach HbA(1c) targets compared with separate administration of iGlar or Lixi. The purpose of this review is to help clinicians understand treatment intensification using iGlarLixi by presenting typical clinical scenarios supported by research evidence. These cases will focus on individuals with T2D inadequately controlled by oral antihyperglycemic drugs, basal insulin, or glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and take into consideration T2D duration, body mass index, incidence of adverse events, and regimen simplicity. Clinical evidence on the efficacy, effectiveness, and safety of iGlarLixi from randomized controlled trials and real-world studies will be discussed in the context of these cases. Springer Healthcare 2021-02-23 2021 /pmc/articles/PMC8004501/ /pubmed/33620694 http://dx.doi.org/10.1007/s12325-020-01614-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Skolnik, Neil Del Prato, Stefano Blonde, Lawrence Galstyan, Gagik Rosenstock, Julio Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes |
title | Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes |
title_full | Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes |
title_fullStr | Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes |
title_full_unstemmed | Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes |
title_short | Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes |
title_sort | translating iglarlixi evidence for the management of frequent clinical scenarios in type 2 diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004501/ https://www.ncbi.nlm.nih.gov/pubmed/33620694 http://dx.doi.org/10.1007/s12325-020-01614-5 |
work_keys_str_mv | AT skolnikneil translatingiglarlixievidenceforthemanagementoffrequentclinicalscenariosintype2diabetes AT delpratostefano translatingiglarlixievidenceforthemanagementoffrequentclinicalscenariosintype2diabetes AT blondelawrence translatingiglarlixievidenceforthemanagementoffrequentclinicalscenariosintype2diabetes AT galstyangagik translatingiglarlixievidenceforthemanagementoffrequentclinicalscenariosintype2diabetes AT rosenstockjulio translatingiglarlixievidenceforthemanagementoffrequentclinicalscenariosintype2diabetes |